The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Both Raloxifene and Estrogen Reduce Major Cardiovascular Risk Factors in Healthy Postmenopausal Women: A 2-Year, Placebo-Controlled Study
Open accessAbstract
Abstract —Currently raloxifene, a selective estrogen receptor modulator, is being investigated as a potential alternative for postmenopausal hormone replacement to prevent osteoporosis and cardiovascular disease. We compared the 2-year effects of raloxifene on a wide range of cardiovascular risk factors with those of placebo and conjugated equine estrogens (CEEs). Analyses were based on 56 hysterectomized but otherwise healthy postmenopausal women aged 54.8±3.5 (mean±SD) years who entered this double-blind study and who were randomly assigned to raloxifene hydrochloride 60 mg/d (n=15) or 150 mg/d (n=13), placebo (n=13), or CEEs 0.625 mg/d (n=15). At baseline and after 6, 12, and 24 months of treatment, we assessed serum lipids, blood pressure, glucose metabolism, C-reactive protein, and various hemostatic parameters. Compared with placebo, both raloxifene and CEEs lowered the level of low density lipoprotein cholesterol by 0.53 to 0.79 mmol/L (all P <0.04) and lowered, at 24 months, the level of fibrinogen by 0.71 to 0.86 g/L (all P <0.05). The effects of raloxifene and CEEs did not differ significantly. In contrast to raloxifene, from 6 months on CEEs increased high density lipoprotein cholesterol by 0.25 to 0.29 mmol/L and reduced plasminogen activator inhibitor-1 antigen by 30.6 to 48.6 ng/mL (all P <0.02 versus both placebo and raloxifene). CEEs transiently increased C-reactive protein by 1.0 mg/L at 6 months ( P <0.05 versus placebo) and prothrombin-derived fragment F1+2 by 0.79 nmol/L at 12 months ( P <0.001 versus placebo). Finally, from 12 months on, CEEs increased triglycerides by 0.33 to 0.56 mmol/L (all P <0.05 versus both placebo and raloxifene). Our findings suggest that in healthy postmenopausal women, raloxifene and estrogen monotherapy have similar beneficial effects on low density lipoprotein cholesterol and fibrinogen levels. These treatments differ, however, in their effects on high density lipoprotein cholesterol, triglycerides, and plasminogen activator inhibitor-1 and possibly in their effects on prothrombin fragment F1+2 and C-reactive protein.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hulley, S. (1998) · JAMA · doi:10.1001/jama.280.7.605 · Cited by 6,216
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162
Valery (1995) · doi:10.1001/jama.1995.03520270033028 · Cited by 2,320
The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.
Colditz, G. A., Hankinson, S. E., Hunter, D. J., Willett, W. C., Manson, J. E., Stampfer, M. J., Hennekens, C., Rosner, B., & Speizer, F. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506153322401 · Cited by 1,487 · cited 1×
“Estradiol, pmol/L 11 (9; 14) 12 (7; 20) 11 (7; 19) 15 (8; 27) 8 (6; 11)”
Walsh, B. W., Schiff, I., Rosner, B., Greenberg, L., Ravnikar, V., & Sacks, F. M. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110243251702 · Cited by 1,152
Plasma Lipoprotein Levels as Predictors of Cardiovascular Death in Women
Bass, K. M. (1993) · Archives of Internal Medicine · doi:10.1001/archinte.1993.00410190045006 · Cited by 331 · cited 1×
“D-dimer, mg/L 22 (17; 28) 26 (17; 40) 16 (11; 25) 18 (11; 31) 30 (18; 47)”
Cited by
Papaioannou, A., Morin, S., Cheung, A. M., Atkinson, S., Brown, J. P., Feldman, S., Hanley, D. A., Hodsman, A., Jamal, S. A., Kaiser, S. M., et al. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.100771 · Cited by 1,749
Bone Mineral Density Thresholds for Pharmacological Intervention to Prevent Fractures
Siris, E. S., Chen, Y.-T., Abbott, T. A., Barrett-Connor, E., Miller, P. D., Wehren, L. E., & Berger, M. L. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.10.1108 · Cited by 1,093
Salpeter, S. R., Walsh, J. M. E., Ormiston, T. M., Greyber, E., Buckley, N. S., & Salpeter, E. E. (2006) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2005.00545.x · Cited by 640
Kanaya, A. M., Herrington, D., Vittinghoff, E., Lin, F., Grady, D., Bittner, V., Cauley, J. A., & Barrett-Connor, E. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-1-200301070-00005 · Cited by 633
for the Women’s Health Initiative Investigators, Margolis, K. L., Bonds, D. E., Rodabough, R. J., Tinker, L., Phillips, L. S., Allen, C., Bassford, T., Burke, G., Torrens, J., et al. (2004) · Diabetologia · doi:10.1007/s00125-004-1448-x · Cited by 599
Metadata
- Authors
- de Valk-de Roo, G. W., Stehouwer, C. D. A., Meijer, P., Mijatovic, V., Kluft, C., Kenemans, P., Cohen, F., Watts, S., & Netelenbos, C.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 1999-12
- Volume
- 19
- Issue
- 12
- Pages
- 2993-3000
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2144006121
- Cited by
- 158
- References
- 7
- FWCI
- 10.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Both Raloxifene and Estrogen Reduce Major Cardiovascular Risk Factors in Healthy Postmenopausal Women: A 2-Year, Placebo-Controlled Study. https://app.cochat.ai/papers/10.1161/01.atv.19.12.2993
- The paper
- de Valk-de Roo, G. W., Stehouwer, C. D. A., Meijer, P., Mijatovic, V., Kluft, C., Kenemans, P., Cohen, F., Watts, S., & Netelenbos, C. (1999). Both Raloxifene and Estrogen Reduce Major Cardiovascular Risk Factors in Healthy Postmenopausal Women: A 2-Year, Placebo-Controlled Study. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/01.atv.19.12.2993
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.